TVTX - Company ID 0001438533
Travere Therapeutics, Inc. (TVTX) reported net income of -$25.55M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$25.55M | +92.1% |
| FY 2024 | -$321.55M | -188.6% |
| FY 2023 | -$111.40M | +60.0% |
| FY 2022 | -$278.48M | -54.6% |
| FY 2021 | -$180.09M | -6.3% |
| FY 2020 | -$169.43M | -15.7% |
| FY 2019 | -$146.43M | -42.6% |
| FY 2018 | -$102.68M | -71.9% |
| FY 2017 |
Travere Therapeutics, Inc. (TVTX) reported net income of -$25.55M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Travere Therapeutics, Inc.'s net income declined from -$14.82K to -$25.55M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$59.73M |
| -24.7% |
| FY 2016 | -$47.90M | -140.9% |
| FY 2015 | $117.24M | +205.7% |
| FY 2014 | -$110.94M | -220.4% |
| FY 2013 | -$34.63M | -14.1% |
| FY 2012 | -$30.34M | -204580.3% |
| FY 2012 | -$14.82K | - |